{"id":"W2619858681","doi":"10.1016/s1470-2045(17)30376-5","title":"Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":539,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; Ottawa Hospital","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation","keywords":"Fulvestrant; Medicine; Breast cancer; Placebo; Internal medicine; Metastatic breast cancer; Oncology; Cancer; Aromatase inhibitor; Estrogen receptor; Tamoxifen; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001280549,0.00204284,0.002922811,0.0004707551,0.000352201,0.0009777867,0.0009705348,0.00186236,0.008628648],"category_scores_gemma":[0.001340508,0.0006501699,0.001969885,0.0004170829,0.001041398,0.001245457,0.0004086075,0.002901,0.001329108],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006861417,"about_ca_system_score_gemma":0.0007091346,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008646791,"about_ca_topic_score_gemma":0.002067159,"domain_scores_codex":[0.9996481,0.0001577481,0.00002094329,0.00006986252,0.0000255513,0.00007778238],"domain_scores_gemma":[0.999571,0.0001330936,0.00009511076,0.00003314492,0.00002431669,0.0001433081],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9805977,0.002557185,0.000170702,0.0007089162,0.0006843523,0.00002185452,0.00002822723,0.0002672507,0.002107849,0.0001090495,0.0007485116,0.0119985],"study_design_scores_gemma":[0.9660429,0.03232917,0.000532939,0.00002440499,0.0002332133,0.00001869184,0.00001399014,0.0001972664,0.0001747058,0.0001078915,0.0003153294,0.000009560312],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9755017,0.01211304,0.000992659,0.001561323,0.001118743,0.003606946,0.001744972,0.0003376392,0.00302302],"genre_scores_gemma":[0.9778525,0.006156651,0.001511508,0.001869483,0.0005746017,0.00414543,0.001386291,0.00004068993,0.006462969],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008628648,"threshold_uncertainty_score":0.02886564,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04915608166519876,"score_gpt":0.3711958041582476,"score_spread":0.3220397224930489,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}